Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Shares Outstanding (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Shares Outstanding for 7 consecutive years, with $101.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 21.66% to $101.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $101.7 million, a 21.66% increase, with the full-year FY2025 number at $101.7 million, up 21.66% from a year prior.
  • Shares Outstanding was $101.7 million for Q4 2025 at Beam Therapeutics, roughly flat from $101.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $101.7 million in Q4 2025 to a low of $61.7 million in Q1 2021.
  • A 5-year average of $79.6 million and a median of $78.7 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: surged 34.29% in 2021, then increased 2.45% in 2024.
  • Beam Therapeutics' Shares Outstanding stood at $68.4 million in 2021, then grew by 4.22% to $71.3 million in 2022, then rose by 14.53% to $81.6 million in 2023, then increased by 2.45% to $83.6 million in 2024, then grew by 21.66% to $101.7 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Shares Outstanding are $101.7 million (Q4 2025), $101.4 million (Q3 2025), and $100.8 million (Q2 2025).